Insider Buying: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Acquires 10,000 Shares of Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of the stock in a transaction on Friday, February 28th. The shares were bought at an average price of $4.76 per share, for a total transaction of $47,600.00. Following the acquisition, the chief executive officer now owns 2,361,730 shares of the company’s stock, valued at approximately $11,241,834.80. The trade was a 0.43 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Mihael Hristos Polymeropoulos also recently made the following trade(s):

• On Tuesday, February 25th, Mihael Hristos Polymeropoulos purchased 10,000 shares of Vanda Pharmaceuticals stock. The shares were bought at an average price of $4.46 per share, for a total transaction of $44,600.00.

Vanda Pharmaceuticals Price Performance

Shares of VNDA stock opened at $4.76 on Friday. The stock has a market cap of $277.58 million, a P/E ratio of -14.88 and a beta of 0.74. Vanda Pharmaceuticals Inc. has a one year low of $3.71 and a one year high of $6.75. The stock has a fifty day moving average price of $4.59 and a 200 day moving average price of $4.80.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.06. The firm had revenue of $53.19 million during the quarter, compared to analysts’ expectations of $51.00 million. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. Equities research analysts anticipate that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Quantinno Capital Management LP bought a new position in shares of Vanda Pharmaceuticals during the fourth quarter valued at $48,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Vanda Pharmaceuticals by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 4,374 shares during the period. XTX Topco Ltd bought a new position in shares of Vanda Pharmaceuticals during the fourth quarter valued at $69,000. Zacks Investment Management bought a new position in shares of Vanda Pharmaceuticals during the fourth quarter valued at $74,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Vanda Pharmaceuticals in the third quarter valued at $84,000. 88.14% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have commented on VNDA shares. StockNews.com started coverage on Vanda Pharmaceuticals in a report on Wednesday, February 5th. They set a “hold” rating on the stock. HC Wainwright increased their price objective on Vanda Pharmaceuticals from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, February 18th.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.